Clinical trial · Interventional
Comparison Study in Pancreatic Fiducial Placement
NCT02376543CI-TRIAL-00047394withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study stopped for change in needle usage
Summary
Brief summary (as posted)
Comparison Study between 19 gauge EUS FNA BNX Needle vs. 22 gauge EUS FNA BNX Needle in Pancreatic Fiducial Placement To Treat Pancreatic Cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 19 Gauge EUS FNA BNX | Device | — | UNRESOLVED |
| 22 Gauge EUS FNA BNX | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 19 Gauge EUS FNA BNX
- description
- Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
- interventionNames
- Device: 19 Gauge EUS FNA BNX
- type
- ACTIVE_COMPARATOR
- label
- 22 Gauge EUS FNA BNX
- description
- Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
- interventionNames
- Device: 22 Gauge EUS FNA BNX
Primary outcomes (2)
- measure
- Total Cost Comparison
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects that plan to undergo CyberKnife treatment for pancreatic cancer 2. Subjects that are deemed physically able to undergo anesthesia (either Monitored Anesthesia Care (MAC) or general anesthesia) 3. Subjects (or the subjects Legally Authorized Representative \[LAR\]) that have agreed to participate in the study and have signed Informed Consent 4. Subjects 18 years of age or older 5. Subject must be able to hold anticoagulants as per institutional standard of care 6. Women of child bearing potential who are not pregnant as proven by a negative pregnancy test Exclusion Criteria: 1. Subjects that are unable to tolerate anesthesia for the procedure 2. Subjects 17 or under 3. Subjects that refuse treatment for pancreatic cancer d Subjects whose anticoagulants cannot be held e. Subjects who have distant metastatic disease f. Subjects who cannot or refuse EUS guided procedures. g Subjects who are pregnant
References
Publications (0)
Data not yet available
No reference posted for this study.